问题1、受行业因素影响，呼吸系统用药收入同比下降了近60%，对于呼吸科产品，是否有具体的策略 来扭转当前的下滑态势？ 回复：尊敬的投资者，您好！受季节性因素影响，公司呼吸类产品销售额出现阶段性下降。2025年前三 季度，公司在止咳类产品市场拓展方面取得显著进展：小儿荆杏止咳颗粒新增覆盖公立医疗机构（等级 医院+基层医院，下同）超过320家，累计覆盖近2,000家，其中等级医院超过1,200家；同时，该产品新 增成人适应症研究进展顺利，II期临床试验已完成，III期临床研究正在有序推进中。强力枇杷膏（蜜 炼）新增覆盖公立医疗机构超过1,200家，累计覆盖近11,000家，其中等级医院超过1,800家。未来，公 司将持续加大在学术推广上的投入，深化医院准入工作，并着力提升核心产品的品牌知名度，以巩固和 扩大市场地位。感谢您对公司的关注!敬请注意投资风险。 证券代码：603998 证券简称：方盛制药 公告编号：2025-092 湖南方盛制药股份有限公司 关于2025年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性 ...

晨会纪要（R3） 晨会纪要 2025 年 09 月 05 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 3765.88 | -1.25 | | 深证成指 | 12118.70 | -2.83 | | 创业板指 | 2776.25 | -4.25 | | 科创 50 | 1226.98 | -6.08 | | 北证 50 | 1538.98 | -0.80 | | 沪深 300 | 4365.21 | -2.12 | 上证指数-沪深 300 走势图 -3% 17% 37% 57% 2024-09 2024-12 2025-03 2025-06 上证指数 沪深300 | 袁闯 | 分析师 | | --- | --- | | 执业证书编号:S0530520010002 | | | yuanchuang@hnchasing.com | | | 周舒鹏 | 研究助理 | zhoushupeng@hnchasing.com 晨会聚焦 一、财信研究观点 【债券研究】债券市场综述 二、重要财经资讯 【宏观经济】央行：9 月 5 日将开展 100 ...

Core Viewpoint - Fangsheng Pharmaceutical announced that its subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a gynecological hemostatic and analgesic granule project, marking a significant step in its drug innovation efforts [1] Group 1 - The clinical trial approval was granted on September 3, 2025, indicating the company's progress in drug development [1] - The project focuses on gynecological applications, which may address specific medical needs in this area [1]

Economic News - The Ministry of Industry and Information Technology and the Ministry of Finance have issued the "Action Plan for Stable Growth in the Electronic Information Manufacturing Industry for 2025-2026," emphasizing the importance of this sector for national economic stability and security [1] - The first central document from the national carbon market signals urgent need for corporate ESG disclosures, with 2,523 A-share companies having disclosed their 2024 ESG reports, representing a disclosure rate of 46.49% [1] - President Trump is set to host a dinner at the White House focusing on artificial intelligence, following a public event led by First Lady Melania Trump aimed at engaging students in AI [1] - The Federal Reserve's latest Beige Book indicates a potential for interest rate cuts, with market expectations for a 25 basis point cut in September rising to 96.6% [1] - Wall Street anticipates price increases for the upcoming iPhone 17, following Apple's commitment to invest $100 billion in U.S. manufacturing over the next four years [1] Company Insights - Kobot announced plans to acquire a 60% stake in Shanghai Kobot Intelligent Technology for 345 million yuan, focusing on automotive intelligent central computing platforms [5] - Southeast Network Framework won a bid for a project in Hangzhou with a contract value of approximately 1.686 billion yuan [5] - Yongzhen Co. has formed a partnership with a leading humanoid robot company to supply precision aluminum alloy components, although this is not expected to significantly impact short-term performance [5] - Fangsheng Pharmaceutical received approval for clinical trials of a new traditional Chinese medicine for postpartum complications [6] - Tianenkang has received a notice of acceptance for the registration application of Dienogest tablets, which are used to treat endometriosis [6] Industry Ratings - China National Offshore Oil Corporation reported a revenue of 207.608 billion yuan for H1 2025, a decrease of 8% year-on-year, with net profit down 12.8% to 69.533 billion yuan [7][8] - The company managed to increase oil production by 4.48% to 296.1 million barrels and natural gas production by 11.97% to 516.2 million barrels, despite a 14.58% drop in Brent crude prices [8][9] - The company is focusing on exploration to secure oil and gas reserves, achieving significant discoveries in both domestic and international projects [9][10] - Shanghai Airport reported a revenue of 6.353 billion yuan for H1 2025, a year-on-year increase of 4.78%, with a notable rise in passenger throughput [11][12] - Non-aeronautical revenue growth was slower than expected, with total non-aeronautical income of 3.437 billion yuan, reflecting challenges in the duty-free segment [13][14]

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a traditional Chinese medicine product aimed at treating postpartum hemorrhage and pain [1]. Group 1 - The approved product is a traditional Chinese medicine formulation for the treatment of postpartum conditions characterized by prolonged lochia, abdominal pain, and other symptoms [1]. - The specific symptoms addressed by the product include excessive lochia, abdominal pain upon touch, dark purple blood clots, fatigue, and lower abdominal distension [1]. - The approval signifies a potential advancement in the company's product pipeline and may enhance its market position in the traditional Chinese medicine sector [1].

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd. (referred to as "Fangsheng R&D"), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its innovative traditional Chinese medicine project, the Gynecological Hemostasis and Pain Relief Granules [1] Group 1 - The National Medical Products Administration has approved the clinical trial for the product, allowing the company to proceed with Phase II and III clinical trials after further refining the clinical trial protocol [1]

Group 1 - The core point of the article is that Fangsheng Pharmaceutical's subsidiary, GuangDong Fangsheng R&D Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its innovative traditional Chinese medicine project, specifically the gynecological hemostatic and analgesic granules [1] - The approval allows the company to conduct Phase II and III clinical trials after further refining the clinical trial protocol [1]